71 related articles for article (PubMed ID: 1942580)
21. Interleukin-2 therapy in relapsed acute myelogenous leukemia.
Meloni G; Vignetti M; Pogliani E; Invernizzi R; Allione B; Mirto S; Sica S; Leoni F; Selleri C; Mandelli F
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S43-7. PubMed ID: 9457393
[TBL] [Abstract][Full Text] [Related]
22. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells.
Blancher A; Roubinet F; Grancher AS; Tremoulet M; Bonaté A; Delisle MB; Calot JP; Pourreau C; Franks C; Ducos J
Eur Cytokine Netw; 1993; 4(5):331-41. PubMed ID: 8117934
[TBL] [Abstract][Full Text] [Related]
23. Clinical application of continuous infusion of recombinant interleukin-2.
West WH
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S11-5. PubMed ID: 2627985
[TBL] [Abstract][Full Text] [Related]
24. A case of cutaneous T cell lymphoma treated with recombinant interleukin 2 (rIL-2).
Nagatani T; Kin ST; Baba N; Miyamoto H; Nakajima H; Katoh Y
Acta Derm Venereol; 1988; 68(6):504-8. PubMed ID: 2467489
[TBL] [Abstract][Full Text] [Related]
25. Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.
Silagi S; Schaefer AE
J Biol Response Mod; 1986 Oct; 5(5):411-22. PubMed ID: 3490544
[TBL] [Abstract][Full Text] [Related]
26. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
[TBL] [Abstract][Full Text] [Related]
27. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
28. Spindle cell hemangioendothelioma: successful treatment with recombinant interleukin-2.
Setoyama M; Shimada H; Miyazono N; Baba Y; Kanzaki T
Br J Dermatol; 2000 Jun; 142(6):1238-9. PubMed ID: 10848757
[No Abstract] [Full Text] [Related]
29. Death from hypovolemic shock caused by perforation of duodenal ulcer in a patient with angiosarcoma of the scalp.
Nishikawa T; Hakuno M; Asano K; Shigematsu N; Shiomi T; Okada Y
Keio J Med; 2002 Mar; 51(1):36-45. PubMed ID: 11951377
[TBL] [Abstract][Full Text] [Related]
30. A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation.
Nagler A; Berger R; Ackerstein A; Czyz JA; Diez-Martin JL; Naparstek E; Or R; Gan S; Shimoni A; Slavin S
J Immunother; 2010 Apr; 33(3):326-33. PubMed ID: 20445353
[TBL] [Abstract][Full Text] [Related]
31. Local activation of immune response in bladder cancer patients treated with intraarterial infusion of recombinant interleukin-2.
Velotti F; Stoppacciaro A; Ruco L; Tubaro A; Pettinato A; Morrone S; Napolitano T; Bossola PC; Franks CR; Palmer P
Cancer Res; 1991 May; 51(9):2456-62. PubMed ID: 2015606
[TBL] [Abstract][Full Text] [Related]
32. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
33. [Usefulness of measurement of hepatic arterial blood flow during surgery to insert an arterial reservoir in unresectable hepatocellular carcinoma].
Yano K; Okimura E; Shimizu R; Uchiyama T; Yoshino S; Hazama S; Murakami T; Suzuki T
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):2982-5. PubMed ID: 2551239
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-2-based immunotherapy for the treatment of metastatic renal cell carcinoma: an analysis of 203 consecutively treated patients.
Figlin R; Gitlitz B; Franklin J; Dorey F; Moldawer N; Rausch J; deKernion J; Belldegrun A
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S92-7. PubMed ID: 9457402
[TBL] [Abstract][Full Text] [Related]
35. Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2.
Grasso M; Torelli F; Scannapieco G; Franzoso F; Lania C
J Immunother; 2001; 24(2):184-7. PubMed ID: 11265776
[TBL] [Abstract][Full Text] [Related]
36. [Case report of epithelioid hemangioendothelioma of the frontal region metastatic to the parotid gland].
Schneider B; ten Cate WJ; Sudermann T; Jahnke K
Laryngorhinootologie; 1998 Dec; 77(12):728-31. PubMed ID: 10036678
[TBL] [Abstract][Full Text] [Related]
37. [Two cases of malignant angioendothelioma possibly succeeded in treatments].
Kashima M; Saito K
Nihon Hifuka Gakkai Zasshi; 1986 Oct; 96(11):1123-32. PubMed ID: 3807011
[No Abstract] [Full Text] [Related]
38. Adoptive immunotherapy of human cancer using low-dose recombinant interleukin 2 and lymphokine-activated killer cells.
Schoof DD; Gramolini BA; Davidson DL; Massaro AF; Wilson RE; Eberlein TJ
Cancer Res; 1988 Sep; 48(17):5007-10. PubMed ID: 3261630
[TBL] [Abstract][Full Text] [Related]
39. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
Atzpodien J; Kirchner H; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
[TBL] [Abstract][Full Text] [Related]
40. Local interleukin-2 therapy of bovine vulval papilloma and carcinoma complex.
Stewart RJ; Jacobs JJ; Koten JW; Den Otter W
Vet Rec; 2010 Nov; 167(21):825-6. PubMed ID: 21262632
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
